Liangyu Zou

Prof. Liangyu Zou


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
BXBocheng Xiong
Bocheng Xiong
CYChao Yang
Chao Yang
XYXiao Yang
Xiao Yang
SLSong Luo
Song Luo
SLShangming Li
Shangming Li
XYXifei Yang
Xifei Yang
Aim: Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease characterized by progressive death of upper and lower motor neurons, leading to generalized muscle atrophy, paralysis, and even death. Mitochondrial damage and neuroinflammation play key roles in the pathogenesis of ALS. In the present study, the efficacy of A‐1, a derivative of arctigenin with AMP‐activated protein kinase (AMPK) and silent information regulator 1 (SIRT1) activation for ALS, was investigated.Methods: A‐1 at 33.3 mg/kg was administrated in SOD1G93A transgenic mice orally from the 13th week for a 6‐week treatment period. Motor ability was assessed before terminal anesthesia. Muscle atrophy and fibrosis, motor neurons, astrocytes, and microglia in the spinal cord were evaluated by H&E, Masson, Sirius Red, Nissl, and immunohistochemistry staining. Protein expression was detected with proteomics analysis, Western blotting, and ELISA. Mitochondrial adenosine triphosphate (ATP) and malondialdehyde (MDA) levels were measured using an assay kit.Results: A‐1 administration in SOD1G93A mice enhanced mobility, decreased skeletal muscle atrophy and fibrosis, mitigated loss of spinal motor neurons, and reduced glial activation. Additionally, A‐1 treatment improved mitochondrial function, evidenced by elevated ATP levels and increased expression of key mitochondrial‐related proteins. The A‐1 treatment group showed decreased levels of IL‐1β, pIκBα/IκBα, and pNF‐κB/NF‐κB.Conclusions: A‐1 treatment reduced motor neuron loss, improved gastrocnemius atrophy, and delayed ALS progression through the AMPK/SIRT1/PGC‐1α pathway, which promotes mitochondrial biogenesis. Furthermore, the AMPK/SIRT1/IL‐1β/NF‐κB pathway exerted neuroprotective effects by reducing neuroinflammation. These findings suggest A‐1 as a promising therapeutic approach for ALS.

18 September 2024 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
HZHuan Zhang
Huan Zhang
CGChuanyue Gao
Chuanyue Gao
DYDeguang Yang
Deguang Yang
LNLulin Nie
Lulin Nie
KHKaiwu He
Kaiwu He
LZLiangyu Zou
Liangyu Zou
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease pathologically characterized by selective degeneration of motor neurons resulting in a catastrophic loss of motor function. The present study aimed to investigate the effect of copper (Cu) exposure on progression of ALS and explore the therapeutic effect and mechanism of Urolithin A (UA) on ALS. 0.13 PPM copper chloride drinking water was administrated in SOD1G93A transgenic mice at 6 weeks, UA at a dosage of 50 mg/kg/day was given for 6 weeks after a 7-week Cu exposure. Motor ability was assessed before terminal anesthesia. Muscle atrophy and fibrosis, motor neurons, astrocytes and microglia in the spinal cord were evaluated by H&E, Masson, Sirius Red, Nissl and Immunohistochemistry Staining. Proteomics analysis, Western blotting and ELISA were conducted to detect protein expression. Mitochondrial adenosine triphosphate (ATP) and malondialdehyde (MDA) levels were measured using an assay kit. Cu-exposure worsened motor function, promoted muscle fibrosis, loss of motor neurons, and astrocyte and microglial activation. It also induced abnormal changes in mitochondria-related biological processes, leading to a significant reduction in ATP levels and an increase in MDA levels. Upregulation of P62 and downregulation of Parkin, PINK1, and LAMP1 were revealed in SOD1G93A mice with Cu exposure. Administration of UA activated mitophagy, modulated mitochondria dysfunction, reduced neuroinflammation, and improved gastrocnemius muscle atrophy and motor dysfunction in SOD1G93A mice with Cu exposure. Mitophagy plays critical role in ALS exacerbated by Cu exposure. UA administration may be a promising treatment strategy for ALS.

4 December 2024 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
XCXiaorui Cui
Xiaorui Cui
MLMingpeng Li
Mingpeng Li
GLGuanxiong Lei
Guanxiong Lei
JWJie Wang
Jie Wang
JPJialin Pan
Jialin Pan
JYJianhui Yan
Jianhui Yan
Background: Brain has been shown to undergo progressive atrophy in patients with Alzheimer’s disease (AD); however, more evidence is needed to elucidate how the brain structure changes during the progression to AD. Here, we observed differences in the cerebral structure among patients with amnestic mild cognitive impairment (aMCI) and patients with AD.Methods: A total of 46 participants were selected and divided into AD, aMCI, and healthy control (HC) groups. Structural magnetic resonance imaging (sMRI) was performed on all participants. Voxel-based morphometry (VBM) and surface-based morphometry (SBM) techniques were utilized to analyze sMRI data so as to identify significant differences among the specific brain regions of these three groups. Then, a correlation analysis was performed on the characteristics of the identified brain regions and the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) cognitive assessment scores.Results: The volume of the left precuneus region, which was identified by voxel-based morphometry, and the thickness of both sides of the inferior parietal, which was identified by surface-based morphometry, were shown to be less in AD/aMCI patients, compared to those of the HC. The correlation analysis showed that there were significant differences between the volume of the left precuneus region and the MMSE/MoCA scores, as well as between the thickness of the left and right sides of the inferior parietal region and the MMSE/MoCA scores.Conclusion: The sMRI characteristics of the identified brain regions were considered to be potential predictive diagnostic biomarkers for AD.Systematic review registration: Identifier: ChiCTR2400092593.

30 November 2024 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
HZHuan Zhang
Huan Zhang
CGChuanyue Gao
Chuanyue Gao
DYDeguang Yang
Deguang Yang
LNLulin Nie
Lulin Nie
KHKaiwu He
Kaiwu He
LZLiangyu Zou
Liangyu Zou

9 November 2024 in Stem Cell Research
Verified
Journal Article
Open access
CHChunyan Huang
Chunyan Huang
LQLiying Qiu
Liying Qiu
WZWenyan Zhou
Wenyan Zhou
CSCongwen Shao
Congwen Shao
XWXichun Wang
Xichun Wang
XXXueqing Xu
Xueqing Xu
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease. Four major genes associated with ALS-SOD1, TARDBP, FUS, and C9orf72-have been identified, with the fused in sarcoma (FUS) gene demonstrating considerable genetic heterogeneity. Our research group has previously established an induced pluripotent stem (iPS) cell line harboring the c.1562G > A mutation in the FUS gene. The objective of this study is to create another iPS cell line featuring the pathogenic c.1126C > T mutation in the FUS gene. This research aims not only to establish a disease model for ALS linked to FUS mutations but also to pave the way for potential therapeutic interventions.

27 January 2026 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
XWXichun Wang
Xichun Wang
YTYe Tang
Ye Tang
QZQiwen Zhang
Qiwen Zhang
BXBaozhen Xiang
Baozhen Xiang
SZSilin Zeng
Silin Zeng
LZLiangyu Zou
Liangyu Zou
Background: The early and accurate identification of Alzheimer’s disease (AD) remains a significant clinical challenge. Integrating novel peripheral blood-based biomarkers with established cerebrospinal fluid (CSF) measures may offer a promising strategy to enhance diagnostic accuracy and risk stratification. Methods: This study enrolled 91 participants who underwent CSF and serum testing. The cohort was randomly divided into a training set ( n = 63) and an internal testing set ( n = 28). External validation was performed using matched data ( n = 30) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (total n = 639). Data collected included demographics, Mini-Mental State Examination (MMSE) total scores, the Functional Activities Questionnaire (FAQ) total scores, CSF phosphorylated tau (pTau181) and amyloid- β (Aβ42) levels, and serum indices such as the albumin-to-globulin (A/G) ratio and platelet-to-lymphocyte ratio (PLR). Predictor selection was performed via univariate and multivariate logistic regression, and a nomogram was developed from the final model. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves with mean absolute error (MAE), and decision curve analysis (DCA). Results: The final predictive model incorporated CSF pTau181, A/G ratio, and PLR (using a cut-off ≥113.22). It demonstrated robust discrimination, achieving an AUC of 0.92 in the training set, 0.86 in the testing set, and 0.83 upon external validation. Calibration was excellent (MAE = 0.039). In the testing set, sensitivity was 0.83 and specificity was 0.86. A higher A/G ratio was associated with a reduced risk of AD progression, whereas a higher PLR was associated with an increased risk. Conclusion: The combined CSF-peripheral blood biomarker model demonstrates robust discrimination and calibration for predicting AD progression. By linking central tau pathology with peripheral nutritional and inflammatory status, it may aid clinical risk stratification and guide management strategies focused on nutrition and inflammation. Further large-scale, prospective validation is warranted.